Drug Development for NASH: A Regulatory Perspective

Time: 8:00 am
day: Day Two


• Understanding the importance of early clinical development and proof-of-concept trials
• Describing the rationale for the choice of the surrogate endpoint reasonably likely to predict clinical benefit
• Identifying the endpoints used to characterize the confirmation of clinical benefit